ArticleGland surgery2026
Personalized survival prediction in young Asian American breast cancer.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Young Asian American women with breast cancer present unique prognostic challenges, yet predictive tools specifically designed for this population are lacking. This study aimed to develop and validate a comprehensive nomogram to predict overall survival (OS) in young Asian American breast cancer patients. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database [2000-2021], we included 3,172 Asian American breast cancer patients aged ≤40 years from an initial population of 109,317 cases. The cohort was randomly divided into training (n=2,224) and validation (n=948) sets. A nomogram incorporating clinicopathological factors was developed using multivariate Cox regression analysis. Results: Integrating T stage, N stage, molecular subtype, and surgical approach, the nomogram demonstrated reasonable predictive capability for OS [concordance index (C-index) =0.759; 95% confidence interval (CI): 0.719-0.799], surpassing that of the conventional staging system (C-index =0.736; 95% CI: 0.678-0.793). The findings underwent internal validation within a split-sample cohort. Conclusions: We developed and validated the novel prognostic nomogram specifically designed for young Asian American breast cancer patients. This tool shows reasonable predictive performance and facilitates personalized treatment planning and risk stratification in this unique population. As our model was evaluated using internal split-sample validation, future true external validation in distinct clinical cohorts is warranted to confirm its generalizability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.